Mezigdomide Expanded Access

Expanded Access for Mezigdomide

  • 202123

What's the purpose of the trial?

This is an expanded access designed to provide access to Mezigdomide for eligible participants.
Trial status

Accepting patients

Phase
Expanded Access
Last Updated

Refer A Patient

Huntsman has made it easy for physicians to refer their patients for plasma cell disorder services and second opinions. To get started, please use the links below or call the Huntsman referral line at (888) 864-8426.

Refer a PatientCall (888) 864-8426

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Mezigdomide is a Cereblon (CRBN) binding compound currently under clinical investigation for multiple myeloma.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Mezigdomide

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 864-8426

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.